The United States continues to face a range of serious threats to its national health security from the deliberate use or accidental release of chemical, biological, radiological, and nuclear (CBRN) agents, as well as from naturally occurring and emerging infectious diseases (EID), including pandemic influenza.
Under the leadership of HHS, the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) is the coordinating body for the federal agencies in charge of protecting the civilian population from potential adverse health impacts of these threats through the use of medical countermeasures (MCMs). These MCMs include medicines, devices, or other medical interventions that can lessen the harmful effects of both intentional and naturally emerging threats.
The 2014 PHEMCE Strategy and Implementation Plan (SIP) provides the blueprints the PHEMCE will follow in the near-, mid-, and long-terms to make the best use of available resources to enhance national health security through the development and effective utilization of medical countermeasures against both intentional and naturally emerging threats.
HHS estimated the funding requirements for NIH, ASPR, FDA, and CDC to pursue medical countermeasure development and purchase in fiscal years 2014-2018, and provided this information to Congress. Agency-specific spending is estimated to be: NIH/NIAID - $9.2 billion; ASPR/BARDA - $5.0 billion; CDC/SNS - $3.1 billion; and FDA - $13.7 million. The out-year funding estimates (FY 2017 & 2018) included in the report were developed without regard to the competing priorities that are considered in the annual development of the President’s Budget and must be considered as budget submissions to Congress are developed in these out-years. So these estimates are subject to change in the future.
The 2014 PHEMCE Strategy and Implementation Plan reflects the HHS commitment, in collaboration with its interagency PHEMCE partners, to provide the nation with a nimble, flexible capacity to rapidly produce and effectively use medical countermeasures in the face of any attack or threat whether known or unknown, novel or reemerging, natural or intentional.
The 2014 PHEMCE SIP reaffirmed the goals and objectives that were established in the 2012 PHEMCE SIP. It also describes the activities and programs that HHS, in collaboration with its interagency partners, is continuing to take to increase MCM preparedness for national health security threats.
Additional information included in the 2014 PHEMCE SIP are:
- An evaluation of progress against 2012 PHEMCE SIP priorities
- Progress in addressing the needs of at-risk populations
- A description of HHS and DoD coordination
- A summary of advanced research and development and procurement awards
- Information regarding the use of funds and authorities originally authorized and provided by Project BioShield
- A summary of PHEMCE interactions with non-federal stakeholders
To ensure that our priorities reflect current scientific progress and fiscal capabilities, this plan is annually assessed and updated to ensure optimal allocation of resources to address high-priority threats. As required by the Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) (Public Law 113-5), a PHEMCE Strategy and Implementation Plan (SIP) is released annually.